Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Strategic Equity Agreement closes, Astellas Pharma and Cytori Therapeutics (CYTX)

CYTX and Astellas Pharma has closed the strategic equity agreement to evaluate the potential of adipose derived stem and regenerative cells for the treatment of serious illnesses for which there is no fundamental treatment.
  • Astellas has  purchased 1.43M unregistered shares of CYTX common stock at $7.00 per share for net proceeds to Cytori of $10M.

Referencing our blog, 12/7/10.